Biggin Hill cyclist aims to take on gruelling Mount Everest-sized challenge
Biggin Hill resident Paul Clark will ride up Stock Hill 240 times in a single day to support The Chartwell Cancer Trust's plans for a new Cancer Information Centre at the Princess Royal University Hospital's Chartwell Unit in Farnborough.
The climb totals more than 12,000 metres of elevation—higher than Mount Everest—and aims to raise £24,000 for the centre, which will offer vital support and information to cancer patients and their families.
Mr Clark said: "This is more than just a physical test; it is about making a real difference for those facing cancer."
His challenge will begin at 9am on June 21, 2025, and will continue through to 9am the following day.
He has committed to riding through the night, regardless of when he reaches his target, to complete the full 24 hours.
Supporters and volunteers will be on hand to cheer him on and collect donations, and the community is encouraged to come out and show their support.
Donations can be made at www.justgiving.com/page/paul-clark-3
Michael Douglas, senior trustee of The Chartwell Cancer Trust, said: "We urgently need more spaces where people affected by cancer can turn for support.
"The new centre will be a place of comfort, advice, and care when people need it most.
"We hope Biggin Hill will come out in force to support Paul.
"Every cheer, every donation, will help build something truly meaningful for local families affected by cancer."
Mr Clark is already receiving backing from businesses and residents, with sponsorship opportunities still available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
These medications could save thousands of lives – but doctors aren't prescribing them
In 2021, varenicline, the most effective single drug for quitting smoking, was withdrawn from the market in the UK because impurities were found at greater levels than is considered safe. Rapidly, varenicline (then sold under its brand names, Champix and Chantix) became unavailable. This was a disaster for public health. Research from University College London estimated that varenicline being unavailable resulted in about 1,890 more avoidable deaths each year because fewer people were successfully quitting smoking. But there was hope. Cytisine (also known as cytisinicline), a naturally occurring plant-based product that had been used for decades in Eastern Europe, and more recently to great effect elsewhere in the world, was licensed in the UK and made available from January 2024. Even so, there was an extended period when neither were available to people trying to quit smoking in the UK (and in other countries, too). But in the UK at least, things were looking up. Based on a limited but growing body of evidence, cytisine probably works as well as varenicline at helping people quit smoking, and it may be better tolerated with fewer side effects. It may also appeal to more smokers who may want to use a natural product rather than a drug designed in a lab. So, with varenicline withdrawn and a similarly effective treatment available, we should have seen lives saved as people who would have taken varenicline were encouraged to try cytisine instead. Why isn't anyone prescribing it? This didn't happen. Cytisine – despite now being licensed and available in the UK – is still shockingly underused. Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when it wasn't even officially available in the UK). Official NHS data from people accessing stop-smoking services in England confirm that only 0.7% were prescribed cytisine in 2024. So why is this? High-profile trials continue to show cytisine's effectiveness for quitting smoking (and even for quitting vaping). Maybe cytisine's relatively complex dosing schedule puts people off. Cytisine starts with six pills a day (one every two hours) and gradually tapers off over a few weeks: more confusing and less convenient than one-a-day varenicline. Another possibility is that the public's attention has shifted. With so much focus in recent years on vaping as a smoking cessation aid, prescription drugs for smoking cessation may have fallen off the radar. It could also be that GPs are reluctant to prescribe cytisine because of its cost and the assumption that local authorities should pay for it, not primary care. While it was once hoped that due to its low-cost availability in Eastern Europe, it would become the 'aspirin of smoking cessation drugs', the licensed product in the UK is now as or more expensive than other drugs. But the simplest explanation is probably the most accurate: not enough people know about cytisine. People who smoke, GPs, pharmacists and even stop-smoking services may not know it's an option. And if no one is talking about it, no one is prescribing it. And even if they do know about it, there may be a lack of confidence in using or prescribing it because it is a new drug. That's a problem. The UK government has made the shift from treating illness to preventing it a central part of its health strategy. Smoking remains the leading cause of preventable death in the country and the world. If we're serious about prevention, then effective smoking cessation support must be top of the agenda. Now, varenicline is available again (without its brand names and reformulated to remove the impurities). This is welcome news, but only 1.1% of past-year smokers reported using varenicline. That's only a quarter of the number from before its withdrawal. This raises an important question: should we return to prescribing varenicline by default, or is it time to consider cytisine as a first-line treatment? Researchers are continuing to learn more about cytisine, but as the evidence in favour of cytisine grows, maybe it needs a PR campaign for both prescribers and people who smoke. None of this is to say that cytisine is a miracle cure, or that it will work for everyone. But that's true of every way to help people quit smoking. Quitting smoking is hard, and people trying to quit need more options, not fewer, and those options need to be visible and accessible. Jonathan Livingstone-Banks is a Lecturer & Senior Researcher in Evidence-Based Healthcare at the University of Oxford. Dimitra Kale is a Senior Research Fellow in Health Psychology at UCL. Lion Shahab is a Professor in Health Psychology at UCL. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
2 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
CBS News
5 hours ago
- CBS News
Maryland fire company hosts screenings as new study shows deadlier risk of certain cancers
For years, research has shown that firefighters are at high risk of being diagnosed with some form of cancer. But a recent study from the American Cancer Society (ACS) suggests certain cancers pose an even deadlier threat for firefighters. These researchers stress the need for things like cancer screenings to help with detecting the cancer early enough for some kind of prevention. These screenings are taking place at the Pikesville Volunteer Fire Company this week, thanks to a federal grant. The study, published in the International Journal of Epidemiology last week, found an increased risk of mortality for most cancers in firefighters, but especially with kidney and skin cancers. For kidney cancer, the study found firefighters had a 40% higher mortality rate than those who weren't firefighters. For skin cancer, the mortality rate is 58% higher. Howie Cohen, who always wanted to be a firefighter, has decades of experience under his belt. "I mentioned it to a friend, and although I had a completely different career, I started volunteering," Cohen said. The Pikesville Volunteer Fire Company is no stranger to a cancer diagnosis. Over the years, several members had died because of the disease. That's why in 2018, Cohen wasn't surprised when he was diagnosed. "I took a test here [at the firehouse]. We had one basic screening, just a blood test, and some markers came up for prostate cancer," Cohen said. "I knew it was coming. My numbers were going up." Even though he's had surgery to remove his cancer, Cohen still looks to get screened when he can. It's why he signed up for a screening Monday at the PVFC firehouse on Sudbrook Lane. Firefighters are 9% more likely to be diagnosed with cancer, as well as 14% more likely to die from cancer, according to research from the CDC and National Institute for Occupational Health and Safety. The ACS stresses that screenings, like the one PVFC is hosting, are critical for prevention. But, when cancer does surface, Cohen said, no matter what, the fire company rallies for each other. "I had a traumatic injury last August, and from the time I was at the hospital until a month after I got home -- I almost had daily visitors from the firehouse," Cohen said. "I'd do the same thing for any other member. We had a member die of cancer three years ago now, and we were there every day." A FEMA grant made this week's screenings at PVFC possible. The goal is to screen more than 50 active firefighters within the company.
